Hofseth Biocare Asa Stock Performance
| HOFBF Stock | USD 0.17 0.00 0.00% |
The company retains a Market Volatility (i.e., Beta) of 0.0, which attests to not very significant fluctuations relative to the market. the returns on MARKET and Hofseth BioCare are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Hofseth BioCare ASA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable fundamental drivers, Hofseth BioCare is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 172.8 M | |
| Total Cashflows From Investing Activities | -37.9 M |
Hofseth |
Hofseth BioCare Relative Risk vs. Return Landscape
If you would invest 17.00 in Hofseth BioCare ASA on November 12, 2025 and sell it today you would earn a total of 0.00 from holding Hofseth BioCare ASA or generate 0.0% return on investment over 90 days. Hofseth BioCare ASA is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Hofseth, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Hofseth BioCare Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Hofseth BioCare for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Hofseth BioCare ASA can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Hofseth BioCare ASA generated a negative expected return over the last 90 days | |
| Hofseth BioCare ASA has some characteristics of a very speculative penny stock | |
| Hofseth BioCare ASA has accumulated 23.79 M in total debt with debt to equity ratio (D/E) of 1.25, which is about average as compared to similar companies. Hofseth BioCare ASA has a current ratio of 0.9, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Hofseth BioCare until it has trouble settling it off, either with new capital or with free cash flow. So, Hofseth BioCare's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hofseth BioCare ASA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hofseth to invest in growth at high rates of return. When we think about Hofseth BioCare's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 87.62 M. Net Loss for the year was (126.46 M) with profit before overhead, payroll, taxes, and interest of 28.51 M. | |
| Hofseth BioCare ASA has accumulated about 30.57 M in cash with (61.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09. | |
| Roughly 53.0% of Hofseth BioCare shares are held by company insiders |
Hofseth BioCare Fundamentals Growth
Hofseth Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Hofseth BioCare, and Hofseth BioCare fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Hofseth Pink Sheet performance.
| Return On Equity | -0.95 | |||
| Return On Asset | -0.19 | |||
| Profit Margin | (1.14) % | |||
| Operating Margin | (1.07) % | |||
| Current Valuation | 103.14 M | |||
| Shares Outstanding | 395.08 M | |||
| Price To Book | 16.71 X | |||
| Price To Sales | 1.21 X | |||
| Revenue | 87.62 M | |||
| EBITDA | (87.72 M) | |||
| Cash And Equivalents | 30.57 M | |||
| Cash Per Share | 0.09 X | |||
| Total Debt | 23.79 M | |||
| Debt To Equity | 1.25 % | |||
| Book Value Per Share | 0.39 X | |||
| Cash Flow From Operations | (61.78 M) | |||
| Earnings Per Share | (0.04) X | |||
| Total Asset | 415.97 M | |||
About Hofseth BioCare Performance
By analyzing Hofseth BioCare's fundamental ratios, stakeholders can gain valuable insights into Hofseth BioCare's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Hofseth BioCare has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Hofseth BioCare has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Hofseth BioCare ASA engages in providing value added biomarine ingredients for human and animal applications in Norway and internationally. The company was founded in 2000 and is headquartered in lesund, Norway. Hofseth Biocare is traded on OTC Exchange in the United States.Things to note about Hofseth BioCare ASA performance evaluation
Checking the ongoing alerts about Hofseth BioCare for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Hofseth BioCare ASA help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Hofseth BioCare ASA generated a negative expected return over the last 90 days | |
| Hofseth BioCare ASA has some characteristics of a very speculative penny stock | |
| Hofseth BioCare ASA has accumulated 23.79 M in total debt with debt to equity ratio (D/E) of 1.25, which is about average as compared to similar companies. Hofseth BioCare ASA has a current ratio of 0.9, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Hofseth BioCare until it has trouble settling it off, either with new capital or with free cash flow. So, Hofseth BioCare's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Hofseth BioCare ASA sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Hofseth to invest in growth at high rates of return. When we think about Hofseth BioCare's use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 87.62 M. Net Loss for the year was (126.46 M) with profit before overhead, payroll, taxes, and interest of 28.51 M. | |
| Hofseth BioCare ASA has accumulated about 30.57 M in cash with (61.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.09. | |
| Roughly 53.0% of Hofseth BioCare shares are held by company insiders |
- Analyzing Hofseth BioCare's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Hofseth BioCare's stock is overvalued or undervalued compared to its peers.
- Examining Hofseth BioCare's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Hofseth BioCare's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Hofseth BioCare's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Hofseth BioCare's pink sheet. These opinions can provide insight into Hofseth BioCare's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Hofseth Pink Sheet analysis
When running Hofseth BioCare's price analysis, check to measure Hofseth BioCare's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Hofseth BioCare is operating at the current time. Most of Hofseth BioCare's value examination focuses on studying past and present price action to predict the probability of Hofseth BioCare's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Hofseth BioCare's price. Additionally, you may evaluate how the addition of Hofseth BioCare to your portfolios can decrease your overall portfolio volatility.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios |